Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 17, 2025

Primary Completion Date

January 1, 2028

Study Completion Date

January 1, 2030

Conditions

Myelodysplastic SyndromesChronic Myelomonocytic Leukemia

Interventions

DRUG

Eltrombopag (EPAG)

50 mg, 28-day cycles, 3 initial cycles + 12 cycles on extension arm (maximum of 15 cycles)

Trial Locations (1)

RECRUITING

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland

All Listed Sponsors

lead

Abhay Singh, MD MPH

OTHER

NCT06630221 - Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations | Biotech Hunter | Biotech Hunter